- 105 Downloads
Prolonged-release mesalazine (Pentasa®2) consists of ethylcellulose-coated microgranules from which mesalazine (known in the US as mesalamine) is released in the small and large intestine in a diffusion-dependent manner.
Dose-dependent improvements in clinical and endoscopic parameters have been reported with prolonged-release mesalazine 2 and 4 g/day in clinical trials in patients with mild to moderately active ulcerative colitis. Induction of clinical and endoscopic remission was achieved in more patients receiving a daily dosage of 4 g/day than in those receiving placebo.
In patients with ulcerative colitis in remission, prolonged-release mesalazine is effective in reducing the rate of relapse. Higher dosages tend to be more effective, and a 12-month remission rate of 64% has been reported for patients treated with a 4g daily dosage of this formulation. Comparative data indicate that prolonged-release mesalazine has similar efficacy in maintaining remission to molar equivalent doses of sulfasalazine.
Data from a study in patients with mild to moderately active Crohn’s disease indicates that higher dosages (4 g/day) of prolonged-release mesalazine are more effective than placebo in reducing disease activity. After 16 weeks’ treatment, 64% of patients receiving a 4 g/day dosage experienced clinical improvement and 43% attained remission. In studies of patients in remission of Crohn’s disease, the formulation appears to be more effective in preventing relapse in patients with isolated small bowel disease than in those with colonie involvement.
The tolerability profile of oral prolonged-release mesalazine is similar to that of placebo and the incidence of adverse events does not appear to be dose-related. Nausea/vomiting, diarrhoea, abdominal pain and dyspepsia occur most frequently, although their incidence is low. Reports of nephrotoxicity during prolonged-release mesalazine treatment are rare.
Conclusions: Oral prolonged-release mesalazine is effective for maintenance and induction of remission of mild to moderately active colitis, both in patients with distal disease and in those with pancolitis. The formulation has similar efficacy to that of equimolar concentrations of sulfasalazine. Prolonged-release mesalazine also appears to be effective in the treatment of Crohn’s disease, and maintenance therapy is of particular value in patients with isolated small bowel involvement. Evidence suggests that higher dosages (3 to 4 g/day) of prolonged-release mesalazine have additional therapeutic benefits over lower dosages in patients with inflammatory bowel disease without increasing the incidence of adverse events.
Mode of Action
The mechanism by which mesalazine exerts its therapeutic actions remains elusive. However, numerous in vitro studies have indicated modulatory actions of mesalazine on the lipid mediators, cytokines and reactive oxygen species involved in the nonspecific inflammation and tissue damage characteristic of ulcerative colitis and Crohn’s disease.
In vitro studies have consistently demonstrated inhibitory effects of mesalazine on leukotriene (LT)B4 synthesis and release from biopsy specimens from individuals with normal colons and from patients with inflammatory bowel disease. Although mesalazine had conflicting effects on prostaglandin (PG)E2 levels, higher concentrations appeared to considerably reduce PGE2 production in colonic mucosa from patients with ulcerative colitis. Mesalazine also appears to reduce in vitro levels of LTC4, 5-hydroxyeicosatetraenoic acid (HETE), 11-, 12-, 15-HETE, PGD2 and platelet-activating factor.
In addition to inhibiting interferon (IFN)-γbinding, mesalazine reduced IFNγ-induced cell permeability and expression of the HLA-DR product of the major histocompatibility complex in colonic epithelial cell lines. Recent evidence suggests that mesalazine reverses the antiproliferative effects of tumour necrosis factor-(TNF)α and inhibits TNFα signalling events in intestinal cells. Mesalazine may also reduce interleukin (IL)-1/1β and IL-2 production.
Mesalazine reduced production of reactive oxygen species and protected against oxidant-induced tissue injury in several in vitro models.
Entry of water into prolonged-release mesalazine microgranules creates a concentration gradient down which mesalazine diffuses, liberating active drug throughout the small bowel and colon.
Prolonged-release mesalazine acts topically in the affected bowel lumen. In volunteers, 18 to 20% of the administered dose was delivered to the jejunoileal segment as solubilised drug, while cumulative colonic delivery was 82% (approximately 75% as intact microgranules) during the first 7 hours after drug administration. Food intake, local pH and diarrhoeal states do not appear to substantially affect the disposition of mesalazine from the prolonged-release formulation.
Mesalazine is primarily metabolised by acetylation in the gut wall and liver, forming acetyl mesalazine. After oral administration, up to 53% of the administered dose is excreted in the urine as mesalazine plus acetyl mesalazine. Faecal excretion accounts for 40% of the administered dose (14 to 19% as unchanged mesalazine, although exact levels of acetylated and nonacetylated mesalazine in different colonie segments are not known).
Prolonged-release mesalazine at dosages up to 4 g/day has been investigated for the maintenance of remission and treatment of mild to moderately active ulcerative colitis and Crohn’s disease. Higher doses of prolonged-release mesalazine (3 to 4 g/day) were generally more effective than low doses (1.5 to 2 g/day) for treatment of acute exacerbations and for maintenance of disease remission.
At dosages of 2 or 4 g/day, the formulation improved clinical and endoscopic findings in patients with active ulcerative colitis, and success of treatment was independent of disease location. At a dosage of 1.5 g/day, the prolonged-release formulation was as effective as sulfasalazine 3 g/day in improving clinical and endoscopic parameters.
The estimated 1-year remission rate in patients with quiescent ulcerative colitis receiving prolonged-release mesalazine 1.5 g/day was similar to that with sulfasalazine 3 g/day (54 vs 46%). A 4g daily dosage of the mesalazine formulation was more effective than placebo in preventing endoscopie and clinical relapse (1-year remission rates 64 vs 38%).
Low dosages (≤2 g/day) of prolonged-release mesalazine had no significant benefits over placebo in patients with mild to moderately active Crohn’s disease. However, the formulation showed benefits compared with placebo at a dosage of 4 g/day in 1 study. In another study, prolonged-release mesalazine 4 g/day produced improvement, but was not statistically better than placebo. In addition to increasing the percentage of patients in remission, or experiencing therapeutic benefit, prolonged-release mesalazine reduced the time to remission and the percentage of treatment failures, compared with placebo. In another study, 16-week remission rates were significantly higher in patients receiving oral budesonide 9 mg/day than in those treated with a4g daily dosage of prolonged-release mesalazine (62 vs 36%).
During prolonged-release mesalazine treatment for maintenance of remission of Crohn’s disease, dosages of ≤2 g/day were not consistently effective in producing benefits over placebo. However, significantly lower relapse rates were reported in patients treated with a 3g daily dosage than in those receiving placebo over a 48-week period. In a noncomparative study of up to 30 months’ duration, dosages of ≤4 g/day (median 3.7 g/day) were effective in maintaining 72% of patients continuously in remission over a 1-year period. Prolonged-release mesalazine showed particular benefit in reducing the rate of relapse in patients with isolated ileal disease. Endoscopie recurrence rates after 1 year in patients with a recent surgical resection of the affected bowel were significantly lower in those receiving prolonged-release mesalazine 3 g/day than in placebo recipients.
Improvements in disease status have been reported in children (aged 9 to 18 years) receiving prolonged-release mesalazine (22 to 53 mg/kg/day) for the treatment of active Crohn’s disease.
There is no evidence of a dose relationship in the adverse events profile of prolonged-release mesalazine and the tolerability profile is similar to that of placebo. The most common adverse events considered related to treatment with the mesalazine formulation at dosages up to 4 g/day were nausea and/or vomiting, headache, abdominal pain, diarrhoea and dyspepsia. Treatment-related adverse events necessitating study withdrawal occurred less commonly in patients receiving a 4g daily dosage of prolonged-release mesalazine than in those receiving placebo.
Although nephrotoxicity has been associated with the use of other mesalazine-containing preparations, impaired renal function does not appear to be associated with use of the prolonged-release formulation. However, as with other mesalazine preparations, precautionary monitoring of serum creatinine levels has been advocated.
Prolonged-release mesalazine appears to be well tolerated in patients intolerant of sulfasalazine. In patients who had experienced infertility as a result of sulfasalazine treatment, sperm quality was improved or normalised after switching to prolonged-release mesalazine treatment.
Dosage and Administration
Oral prolonged-release mesalazine at dosages up to 4 g/day is indicated for the induction of remission and treatment of mild to moderate ulcerative colitis in adults. For patients with quiescent disease, the recommended starting dosage is 1.5 g/day in 2 or 3 divided doses. However, evidence from clinical trials of dosages up to 4 g/day indicates a dose-dependent increase in efficacy.
No US or UK dosage recommendations are available for the use of prolonged-release mesalazine in the management of Crohn’s disease. However, individualised dosage of up to 4 g/day in divided doses is generally recommended for the treatment of active disease and maintenance of remission in other countries.
Prolonged-release mesalazine should not be used in patients with known sensitivity to salicylates or in those with severe renal and/or liver impairment, and is not recommended for use in children. The formulation should be used with caution during pregnancy.
KeywordsUlcerative Colitis Sulfasalazine Mesalazine Active Ulcerative Colitis Balsalazide
- 2.Azad Khan AK, Piris J, Truelove SC. An experiment ot determine the active therapeutic moiety of sulphasalazine. Lancet 1979; II(8044): 892–5Google Scholar
- 19.Gertner DJ, Rampton DS, de Nucci G, et al. Eicosanoid release by rectal mucosa in vitro in ulcerative colitis: effects of conventional and potential new therapies. Eur J Gastroenterol Hepatol 1992; 4: 837–41Google Scholar
- 22.Rachmilewitz D, Karmeli F, Eliakim R. Platelet-activating factor — a possible mediator in the pathogenesis of ulcerative colitis. Scand J Gastroenterol 1990; 25 Suppl. 172: 19–21Google Scholar
- 26.Mazlam MZ, Montazeri G, Hodgson HJF. The effects of some anti-inflammatory agents on cytokine release from human monocytes in vitro. Eur J Gastroenterol Hepatol 1993; 5: 515–20Google Scholar
- 32.Eliakim R, Kanneli F, Razin E, et al. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulphasalazine and prednisolone. Gastroenterology 1988; 95(5): 1167–72Google Scholar
- 45.Keshavarzian A, Sedghi S, Kanofsky J, et al. Excessive production of reactive oxygen metabolites by inflamed colon: analysis by chemiluminescence probe. Gastroenterology 1002; 103(1): 177–85Google Scholar
- 46.Prónai L, Yukinobu I, Lang I, et al. The oxygen-centered radicals scavenging activity of sulphasalazine and its metabolites. A direct protection of the bowel. Acta Physiol Hung 1992; 80: 317–23Google Scholar
- 55.Wilding IR. A scintigraphic study to evaluate what happens to Pentasa® and Asacol® in the human gut. Pract Gastroenterol 1999: 1–8Google Scholar
- 61.Bondesen S, Tage-Jensen U, Jacobsen O, et al. 5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. Eur J Clin Pharmacol 1986; 31: 23–6Google Scholar
- 63.Daneshmend TK, Hendrickse M, Salzmann M, et al. Does systemic absorption of 5-aminosalicylic acid from olsalazine (Dipentum®) and mesalazine (Asacol® and Pentasa®) differ significantly in ulcerative colitis? [abstract]. Gut 1994; 35 Suppl. 4: 233Google Scholar
- 65.Christensen LA, Rasmussen SN, Hansen SH. Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations. Acta Obstet Gynecol Scand 1994; 74: 399–402Google Scholar
- 71.Munakata A, Yoshida Y, Muto T, et al. Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis. J Gastroenterol 1995; 30 Suppl. 8: 108–11Google Scholar
- 72.Farup PG, Oddsson E, Hinterleitner T. Mesalamine 4 g prolonged release granules b.i.d. and q.i.d. versus tablets q.i.d. for mild/moderate ulcerative colitis [abstract]. Gastroenterology 1999; 116(2): A713Google Scholar
- 78.Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group [see comments]. Gastroenterology 1993; 104: 1293–301Google Scholar
- 82.Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn’s disease. A 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987; 22: 877–83Google Scholar
- 84.Gendre J-P, Mary J-Y, Florent C, et al. Oral mesalamine (Pentasa) as maintenance treatment in Crohns disease: a multicenter placebo-controlled study [in French]. Ann Gastroenterol Hepatol 1993; 29: 251–6Google Scholar
- 86.Sutherland LR, Martin F, Bailey RJ, et al. 5-Aminosalicylic acid (Pentasa) in the maintenance of remission of Crohn’s disease [abstract]. Gastroenterology 1995; 108 Suppl.: 924Google Scholar
- 87.Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopie recurrence after intestinal resection for Crohn’s disease. Italian Cooperative Study Group. Gastroenterology 1995; 108: 345–9Google Scholar
- 89.Bondesen S, Danish 5-ASA-group. Mesalazine (Pentasa) as prophylaxis in Crohn’s disease. A multicenter, controlled trial [abstract]. Scand J Gastroenterol 1991; 26 Suppl. 183: 68Google Scholar
- 98.Janowski M, Laglenne S, Beaufils F. Hypersensitivity pneumopathy during treatment with mesalazine (Pentasa®). The value of bronchoalveolar lavage [in French]. Rev Med Interne 1992; 13: 545Google Scholar
- 99.Besseau M, Delchier JC, Blazquez M, et al. Acute pancreatitis induced by mesalazine (Pentasa) [in French]. Gastroenterol Clin Biol 1991; 15(2): 174–5Google Scholar
- 104.Tennenbaum R, Marteau P, Elefant E, et al. Pregnancy outcome in inflammatory bowel disease [in French]. Gastroenterol Clin Biol 1998; 23(5): 464–9Google Scholar
- 117.Roberts Pharmaceuticals. Pentasa prescribing information. Eatontown, New Jersey, USA, 1998Google Scholar
- 118.Pentasa data sheet. Ferring Pharmaceuticals. In: ABPI Compendium of Data Sheets and Summaries of Product Characteristics. London: DataPharm Publications Ltd, 1999: 437–8Google Scholar
- 121.Glickman RM. Inflammatory bowel disease: ulcerative colitis and Crohn’s disease. In: Fauci AS, Braunwald E, Isselbacher KJ, et al., editors. Harrison’s principles of internal medicine. 14th ed. v. 2. New York: McGraw-Hill, 1998: 1633–45Google Scholar
- 125.Singleton JW, Law DH, Kelley Jr ML, et al. National Cooperative Crohn’s Disease Study: adverse reactions to study drugs. Gastroenterology 1979; 44 (4 Pt 2): 870–82Google Scholar
- 126.Camilla C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997; 113: 1465–73Google Scholar
- 128.Olaison G, Smedh K, Sjödahl R. Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33(3): 1150–1Google Scholar